Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Adiponectin and Mortality in Patients with Chronic Kidney Disease

Menon, Vandana, Li, Lijun, Wang, Xuelei, Greene, Tom, Balakrishnan, Vaidyanathapuram, Madero, Magdalena, Pereira, Arema A., Beck, Gerald J., Kusek, John W., Collins, Allan J., Levey, Andrew S., Sarnak, Mark J.·2006·Journal of the American Society of Nephrology

Abstract

Adiponectin is presumed to possess antiatherogenic and cardioprotective properties. Limited data exist on the relationship between adiponectin and mortality in the earlier stages of chronic kidney disease. The Modification of Diet in Renal Disease study was a randomized, controlled trial that was conducted between 1989 and 1993. Adiponectin was measured in frozen samples that were obtained at baseline (N = 820). Survival status and cause of death, up to December 31, 2000, were obtained from the National Death Index. Multivariable Cox models were used to examine the relationship of adiponectin with all-cause and cardiovascular mortality. Mean +/- SD age was 52 +/- 12 yr, and mean +/- SD glomerular filtration rate (GFR) rate was 33 +/- 12 ml/min per 1.73 m2. Eighty-five percent of participants were white, and 60% were male. Mean +/- SD adiponectin was 12.8 +/- 8.0 mug/ml. Triglycerides, insulin resistance, glucose, body mass index, GFR, C-reactive protein, and albumin were inversely related and proteinuria and HDL cholesterol were directly related to adiponectin. During the 10-year follow-up period, 201 (25%) participants died of any cause, and 122 (15%) from cardiovascular disease. In multivariable adjusted Cox models, a 1-mug/ml increase in adiponectin was associated with a 3% (hazard ratio 1.03; 95% confidence interval 1.01 to 1.05; P = 0.02) increased risk for all-cause and 6% (hazard ratio 1.06; 95% confidence interval 1.03 to 1.09; P < 0.001) increased risk for cardiovascular mortality. High, rather than low, adiponectin is associated with increased mortality in this cohort of patients with chronic kidney disease stages 3 to 4. Further studies are necessary to confirm this association and to elucidate the underlying mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2006040331

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 283

Metadata

Authors
Menon, V., Li, L., Wang, X., Greene, T., Balakrishnan, V., Madero, M., Pereira, A. A., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Sarnak, M. J.
Venue
Journal of the American Society of Nephrology
Published
2006-09
Volume
17
Issue
9
Pages
2599-2606
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2123747735
Cited by
283
References
42
FWCI
16.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adiponectin and Mortality in Patients with Chronic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2006040331
The paper
Menon, V., Li, L., Wang, X., Greene, T., Balakrishnan, V., Madero, M., Pereira, A. A., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Sarnak, M. J. (2006). Adiponectin and Mortality in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2006040331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.